Theratechnologies Inc. Common - THTX STOCK NEWS

Theratechnologies (THTX) presented new data at the 34th EORTC-NCI-AACR Symposium showcasing high expression of SORT1 in various solid tumors, indicating its potential as a novel anticancer therapeutic target. The study involved 1,446 cancer samples, revealing significant SORT1 expression in cancers like breast, ovarian, and endometrial, while showing minimal expression in normal tissues. These findings support ongoing clinical trials of TH1902, a SORT1-targeted peptide-drug conjugate, aiming to improve cancer treatment.

Theratechnologies (THTX) reported a strong Q3 2022, with consolidated revenue growth of 17% to $20.8 million and North American revenue growth of 19%. The company is on track to meet its FY2022 revenue guidance of $79-$82 million. Sales of EGRIFTA SV® and Trogarzo® increased by 14.7% and 19.7%, respectively. Notably, the TH1902 Phase 1 trial is proceeding as planned, showing signs of efficacy in specific cancer patients. Additionally, a $100 million credit agreement has extended the company's financial runway, enabling the retirement of convertible notes.

Theratechnologies (THTX) announced the upcoming presentation of data on SORT1 expression in various cancers at the EORTC-NCI-AACR symposium from October 26-28, 2022. This data supports SORT1 as a target for anticancer therapies. The study involves the peptide-drug conjugate TH1902, currently being evaluated in a first-in-human trial across eight solid tumor types. The presentation will be led by Dr. Guylaine Roy, highlighting the significance of SORT1 in oncology and potential impacts on treatment innovation.

Theratechnologies announced FDA approval for Trogarzo® (ibalizumab-uiyk) to be administered via a 30-second undiluted IV push every two weeks, simplifying treatment for patients with multidrug-resistant HIV-1. This new method enhances convenience for clinics, facilitating wider administration. The safety profile of Trogarzo® administered via IV push is comparable to traditional IV infusion. This decision is backed by Phase 3 trials that confirmed safety and pharmacokinetics. Trogarzo® previously received FDA approval in March 2018 for intravenous infusion.

Theratechnologies announced it will release its third quarter financial results for fiscal 2022, ending on August 31, on October 13, 2022. A conference call will take place at 8:30 AM ET to discuss these results and other business updates, featuring CEO Paul Lévesque and other management team members.

Participants should dial in at least ten minutes early. The call can also be accessed via webcast.

MONTREAL, Sept. 19, 2022 – Theratechnologies (THTX) announced that their CEO, Paul Levesque, will join the "Novel Targets in Oncology: Risk vs. Reward" panel at the Cantor Oncology Conference on September 28, 2022, at 9:00 a.m. ET in New York City. The event is exclusive to conference attendees. Alongside Levesque, CFO Philippe Dubuc and CMO Dr. Christian Marsolais will engage in various meetings during the conference. Theratechnologies focuses on developing innovative therapies for unmet medical needs, emphasizing their commitment to advancements in health.

Theratechnologies has published a preclinical study demonstrating that its investigational drug TH1902 exhibits superior anticancer activity against ovarian and triple-negative breast cancer stem-like cells compared to docetaxel. The study suggests TH1902 can bypass resistance mechanisms associated with traditional chemotherapy, potentially reducing tumor growth by 80% in preclinical models. Having received FDA Fast-Track Designation, TH1902 is currently in a Phase 1 trial across multiple solid tumors, marking a significant advancement in targeting cancer stem cells.

Theratechnologies (NASDAQ: THTX) will participate in the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 1:00 p.m. ET. Paul Levesque, CEO, will engage in a fireside chat during the event. Interested investors can access the live webcast here, with an archive available for 90 days following the conference.

Theratechnologies (THTX) presented new data at the AIDS 2022 conference showing that Trogarzo (ibalizumab) maintains long-term viral suppression in HIV patients, regardless of partially active agents. Predictive pharmacokinetic modeling indicated that new administration methods could mimic intravenous infusion kinetics. The data also demonstrated synergistic effects between Trogarzo and various antiretrovirals, such as dolutegravir and lenacapavir. These findings suggest potential improvements in treatment regimens for heavily treatment-experienced HIV populations, aiming for simpler and more effective therapies.